GSK's Zantac Litigation Heads to Delaware Supreme Court
Ticker: GLAXF · Form: 6-K · Filed: Aug 28, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 28, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: litigation, legal-update, pharmaceutical
TL;DR
Delaware Supreme Court to review Zantac case - GSK litigation continues.
AI Summary
GSK plc announced on August 27, 2024, that the Delaware Supreme Court will review a Superior Court's Daubert decision concerning the Zantac (ranitidine) litigation. This development pertains to the ongoing legal proceedings related to the drug.
Why It Matters
This legal development could have significant financial implications for GSK depending on the outcome of the Delaware Supreme Court's review of the Zantac litigation.
Risk Assessment
Risk Level: medium — The Zantac litigation has the potential for significant financial impact on GSK, making it a notable risk factor.
Key Players & Entities
- GSK plc (company) — Registrant and subject of the filing
- Zantac (ranitidine) (product) — Subject of the litigation
- Delaware Supreme Court (company) — Court reviewing the case
- Superior Court (company) — Court that made the initial Daubert decision
- 27 August 2024 (date) — Date of the announcement
FAQ
What specific decision by the Superior Court is the Delaware Supreme Court reviewing?
The Delaware Supreme Court is reviewing the Superior Court's 'Daubert decision' concerning the Zantac (ranitidine) litigation.
When was this announcement made by GSK plc?
The announcement was issued on 27 August 2024.
What is the subject of the ongoing litigation mentioned in the filing?
The litigation concerns Zantac (ranitidine).
Which court will now review the Daubert decision?
The Delaware Supreme Court will review the Daubert decision.
What is the filing form type and its purpose?
The filing is a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Stats: 876 words · 4 min read · ~3 pages · Grade level 14.1 · Accepted 2024-08-28 07:31:44
Filing Documents
- a8948b.htm (6-K) — 35KB
- 0001654954-24-011164.txt ( ) — 36KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: August 28, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc